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Available online 18 January 2017AbstractIntroduction: Intraoperative touch imprint cytology (TIC) of the sentinel lymph node(s) (SLN(s)) in the treatment of breast cancer has
significantly reduced the number of axillary block dissections (ABD) required during second surgeries. Based on recent studies, ABD
was not considered necessary if the presence of tumor cells/micrometastasis was confirmed in the SLN(s) or in the case of macrometastases
in a patient group meeting the inclusion criteria for the ACOSOG Z0011 study. Our aim was to determine the sensitivity and usefulness of
TIC with regard to these results.
Methods: TICs of the SLN(s) were examined in 1168 patients operated on for breast cancer. The method was also analyzed retrospectively
based on the guidelines for the Z0011 study. During TIC, new samples were cut every 250 mm; impression smears were evaluated after
being stained with hematoxylin eosin.
Results: TIC confirmed metastasis in 202 cases (202/1168, 17.29%). Metastasis was confirmed in SLN(s) in 149 additional cases during a
final histological examination. The sensitivity of TIC was found to be 57.18%, and its specificity was 99.63%. An analysis was then per-
formed except for cases that met the inclusion criteria for the Z0011 study and with metastasis smaller than 2 mm (micrometastasis/isolated
tumor cells) considered to be positive during intraoperative cytology. The sensitivity of the method decreased to 34.23%, while its spec-
ificity was still high at 99.76%.
Conclusions: Based on the new guidelines for ABD, imprint cytology cannot be considered a beneficial and cost-effective intervention in
the surgical treatment of early breast cancer.
 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
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1,2Introduction
The introduction of sentinel lymph node biopsy (SLNB)
in the treatment of early breast cancer 20 years ago signif-
icantly reduced the number of radical surgical interventionshor. Department of Surgery, University of Szeged, Albert S
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sevier Ltd, BASO ~ The Association for Cancer Surgery,and the number of axillary block dissections (ABD). In-
traoperative analysis of the sentinel lymph node(s) has been
used increasingly, as surgeries performed in two sessions
can be avoided with this method in most cases.1,3zent-Gy€orgyi Clinical Center, Sz}okefalvi-Nagy B. u. 6., Szeged, H-6720,
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cytology, frozen section histology and a nucleic acid ampli-
fication study. The specificity and sensitivity of these exam-
inations are similar. The sensitivity of the nucleic acid
amplification study is 76.9e98.2%, and that of frozen sec-
tion histology and imprint cytology varies between 68.49
and 98.81%. The specificity of all three methods is consid-
ered almost 100%.4e7
Surgical treatment of the axilla has changed signifi-
cantly, particularly with regard to the indication for supple-
mentary ABD. Based on the results of several prospective
studies, ABD is not indicated for positive sentinel lymph
nodes containing isolated tumor cells (ITC, <0.2 mm)
and micrometastases (<2 mm), adjuvant therapy being
sufficient.8e10 The results were also described in several in-
ternational guidelines.9,11 Axillary block dissection is not
necessarily required for patients with wide excision and
sentinel lymph node biopsy for stage T1 or T2 breast cancer
with sentinel lymph nodes containing no more than 1e2
macrometastases, according to the ACOSOG Z0011 study
published in 2011 (neoadjuvant therapy is an exclusion cri-
terion as well), as additional surgical treatment neither in-
creases survival significantly nor reduces the incidence of
axillary recurring tumors.8 In these cases, adjuvant sys-
temic treatment and complete irradiation of the breast are
sufficient.8,11e17 According to the ACOSOG Z0011 study
criteria, a consensus conference held in St. Gallen in
2013, the Guidelines of the American Association of
Oncology (NCCN) and axillary block dissection may be
omitted.8,13,14
According to several studies, ABD is an equivalent ther-
apeutic alternative to targeted axillary radiation.15e17
Knowledge of treatment alternatives and participation in
treatment selection represent a growing demand among pa-
tients. However, in the case of axillary block dissection per-
formed for positive imprint cytology, patients cannot
participate in the therapeutic decision.
In conclusion, the routine use of imprint cytology should
be reconsidered. In our study, imprint cytology results were
examined and analyzed retrospectively based on new na-
tional guidelines on the treatment of the axilla. Moreover,
we analyzed the cost and time of breast surgery taking
into account the necessity of imprint cytology.sensitivity ¼ realpositivecases=realpositivecases þ falsenegativ
specificity ¼ realnegativecases=realnegativecases þ falsepositiPatients and methods
Between 2008 and 2014, a total of 1673 patients under-
went surgery in our institution for invasive breast cancer
and other breast malignancies. In this period, 1168 patients
who were suffering from consecutive early invasive breast
carcinoma and whose preoperative axillary US þ FNA
did not show axillary lymph node metastasis were exam-
ined with imprint cytology of the SLN(s).
Sentinel lymph nodes were removed with the double
tracer method published by Albertini in 1996.18 On the
day before the surgery (but at least four hours before the
surgery), human colloidal albumin was administered with
isotope (99mTc) tracing under ultrasound or X-ray guid-
ance near the lesion. A lymphoscintigraphic (static) exam-
ination was then performed to determine the projection of
SLN(s) and lymphatic drainage. The patent blue dye was
periareolarly. The SLN(s) were identified with a manual
gamma camera.
The technique for touch imprint cytology (TIC) was as
follows: the cut surface of the fresh sample prepared
from a lymph node (250 mm slices) was pressed on a slide,
and then an impression smear was prepared. The resulting
imprint cut surfaces were fixed in 95% ethanol for 5e6 s,
and the samples were evaluated after hematoxylin eosin
staining. Every SLN underwent a standard histological ex-
amination later.
We allocated the sensitivity and specificity of TIC based
on the intraoperative and final histological result. Based on
the final histological examination of the sentinel lymph no-
de(s), we selected patients in whose cases performing an
ABD is no longer justified according to the new interna-
tional recommendations (ITC, micro- and macrometasta-
ses, which meet the criteria for ACOSOG Z0011) and
thus there is no need for intraoperative lymph node analysis
either. Based on these data, the imprint cytology results
were re-evaluated and compared with non-modified data.StatisticsWe studied the sensitivity and specificity of imprint
cytology with the scheme below:ecases
vecases
Table 2
Patients meeting the criteria for the Z0011 study and with a positive
imprint cytology.
Total %
1254 Z. Horvath et al. / EJSO 43 (2017) 1252e1257We used the SPSS (Statistical Package for the Social
Sciences) programme for comparing the operating time.
We analyzed the data two-sample T-test. The study has
been approved by the local Ethics Committee.Number of patients 117 100
Imprint cytology results
Positive 116 99.15
Negative 1 0.85
False negative 0
False positive 1 0.85
Number of final, positive histological examinations 116
Type of surgery
Excision 117 100
Mastectomy 0 0
Average tumor size (mm) 20.56286
Average number of SLNBs 1.97
ABDs
Performed in one session 111 94.87
Supplementary 2 1.71
Not performeda 4 3.42
a Axillary block dissection was not performed in four cases when a pa-
tient made a request in advance to that effect or in the presence of
micrometastases.Results
In our Department, TIC was performed for invasive
breast tumor in 1168 cases during the period under exami-
nation. The average age of the patients was 58.63 (25e88)
years. TIC was positive in 202 cases in 17.29% (202/1168)
of the cases. A total of 2101 lymph nodes were sent for
imprint cytology, which is an average of 1.8 (1e6) lymph
nodes per patient.
During a final histological examination of the samples,
metastasis was found in 149 additional previously (intrao-
peratively) negative sentinel lymph nodes (false negative
cases: 149/1168 [12.75%]), and metastasis was not
confirmed in three cases found to be positive with imprint
cytology (false positive cases: 3/149 [0.25%]). The sensi-
tivity of the imprint cytology was 57.18%, with a speci-
ficity of 99.63% (Table 1).
A total of 202 axillary block dissections were performed
in one session, and then 80 block dissections were per-
formed on a separate occasion. In 64 cases, an ABD was
not performed, as the patient had not given his consent
for the intervention, the patient had chosen adjuvant
chemotherapy, or the oncoteam had not recommended
additional surgery due to the presence of micrometastasis.
At that point, patients meeting the inclusion criteria for
the Z0011 study (n ¼ 117) and seven patients not meeting
the criteria for Z0011 but with micrometastasis (n ¼ 7)
were excluded from the positive cases by intraoperative ex-
amination (Tables 1 and 2), and then the sensitivity and
specificity of the method were recalculated.
After screening, 78 positive (number of positive
cases ¼ 202 minus number of patients meeting criteriaTable 1
Imprint cytology results (1 May 2008e31 Dec 2014).
Total %
Number of patients 1168 100
Imprint cytology results
Intraoperative (positive) 202 17.3
Intraoperative (negative) 966 82.7
False negative 149 12.76
False positive 3 0.25
Number of positive final histological examinations 348 29.79
Number of negative final histological examinations 820 70.21
Type of surgery
Excision 883 75.6
Mastectomy 285 24.4
Average tumor size (mm) 19.61
Average number of SLNBs 1.8
ABDs 284 24.32
In one session 204 17.47
Supplementary 80 6.85for Z0011 [n ¼ 117] and number of patients not meeting
criteria for Z0011 but with micrometastasis [n ¼ 7]), two
false positive, 149 false negative and 966 negative cases
were found in the repeated imprint cytology group. Sensi-
tivity fell to 34.23%, and specificity remained 99.76%
(Table 3).
As can be seen on Table 4, axillary block dissection was
performed in 284 cases, but, based on the new guidelines,
only 105 cases were indicated. 179 cases, that is, 15.32%
of the cases, were performed unnecessarily.
As the results were processed, the average size of the
metastases and the distribution of micro- and macrometa-
stases in false negative and positive cases were examined
as well (Table 5). In positive cases, the average size of
the micrometastases was 1.52 mm, while that of the macro-
metastases was 8.33 mm. The average size of the microme-
tastases was 1.1 mm, while that of the macrometastases was
4.79 mm in the false negative group. Therefore, it can be
concluded that imprint cytology cannot be considered a
sensitive intervention for surgeries on smaller metastases.
The costs of ABDs performed with imprint cytology and
with supplementary imprint cytology were compared in
financial terms. (The costs of SLNBs and ABDs performed
during surgery are similar.) During imprint cytology, an
average of five cut surfaces is prepared of the lymph
node. A cut surface costs V32.50. The average price of his-
tology performed during surgery is therefore 1.8*V32.50,
that is, V58.52. An ABD costs V431.17. Based on the re-
sults, the 1168 imprint cytologies cost V68,359.23, while
the 76 supplementary ABDs cost V32,768.49. Therefore,
the difference is V35,586.73. Patient hospital stay after
ABD is longer (about one day) and more out-patient visits
are required, thus further increasing the difference in ex-
penses. This represents an extra charge of about V100
Table 4
Distribution of axillary block dissections.
Total number of ABDs
Imprint Supplementary ABDs 80 284
ABDs performed in one session 204
Positive cases according to Z0011 criteria Supplementary ABDs 2 114
ABDs performed in one session 112
False negative cases according to Z0011 criteria Supplementary ABDs 56 58
ABDs performed in one session 2
Cases not meeting Z0011 criteria but involving micrometastasis Supplementary ABDs 0 7
ABD performed in one session 7
Total Supplementary ABDs 22 105
ABDs performed in one session 83
Table 3
Results modified in accordance with the criteria.
Imprint (all cases) Cases meeting
Z0011 criteria
Cases not meeting Z0011 criteria but
involving micrometastasis
Results recalculated
Number of patients 1168 117 7 1168
Imprint
Positive 202 117 7 78
Negative 966 0 0 966
Final histology
Positive 348 116 7 225
False positive 3 1 0 2
False negative 149 0 0 149
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ined the average duration of breast surgery with and
without imprint cytology. Surgeries were longer by approx-
imately 1.6e5 min when cytology was used, and the differ-
ence was non-significant (data not shown).
Discussion
The introduction of SLNB has been a milestone in the
treatment of early breast cancer, as it has significantly
reduced the number of axillary block dissections and simi-
larly improved staging and oncology/complex treatment of
breast cancers. Simultaneously, intraoperative examination
of the sentinel lymph node(s) has been introduced, and,
as a result, the number of surgeries performed in two stages
and, consequently, both the burden on the patients and sur-
gical costs have decreased.
According to recent studies and guidelines, in cases
meeting certain criteria, such as isolated tumor cells,Table 5
Lymph node metastases in false negative and false positive cases.
Sizes of
metastases (mm)
Number of
metastases
Distri
all me
Positive cases
Micrometastases 1.52 13 3.73
Macrometastases 8.33 187 53.58
False negative cases
Micrometastases 1.10 69 19.77
Macrometastases 4.79 80 22.92sentinel lymph nodes with micrometastasis and no more
than two macrometastases, ABD may be omitted, as it
does not increase the risk of overall mortality and locally
recurring cancer.8,9,11 Similarly, the indication for ABD is
reduced by clinical studies supporting the fact that axillary
radiation is an alternative treatment option to surgery, but it
is associated with lower morbidity.15e17 Axillary radio-
therapy does not pose an increased risk to survival and
locally recurring cancer, and the incidence of lymphedema,
which is primarily responsible for morbidity, is signifi-
cantly decreased as well. Another important factor is the
fact that in the case of axillary block dissection performed
for positive imprint cytology, the patient is unable to partic-
ipate in the therapeutic decision and choose from among
therapeutic options.
These factors suggest a reconsideration of the routine
use of imprint cytology. Based on our results, the sensitivity
of imprint cytology is 57.18%, its specificity is 99.63%, and
these values are consistent with international data. (Thebution in % of
tastases
Distribution in % of
all micro-metastases
Distribution in % of
all macro-metastases
15.85
70.3
84.15
29.7
1256 Z. Horvath et al. / EJSO 43 (2017) 1252e1257sensitivity of imprint cytology varies between 68.49 and
98.81%, with a specificity of approximately 100%).5,19e21
With regard to metastasis sizes and distribution, imprint
cytology is less suited to detecting metastases of 2 mm or
smaller, with 84.15% of micrometastases remaining unde-
tected, but 70.3% of macrometastases can be detected
with this method.
However, according to the latest guidelines, the sensi-
tivity of imprint cytology (based on cases with therapeutic
consequences) is only 34.23% (with unchanged specificity).
This sensitivity value is so low that the usability of this
method is questionable. ABD was only indicated in 9%
of the patients in the period under examination (105/
1168). However, based on the new guidelines, supplemen-
tary lymph node dissection was performed “unnecessarily”
in 15.32% of the patients (179/1168).
It is not insignificant that imprint cytology increased sur-
gical costs and the duration of surgery unnecessarily in a
large percentage of the patients (91%). Imprint cytology
and surgical costs are significantly higher in Western Eu-
rope and the United States; differences in costs (cost effec-
tiveness) are therefore more significant in those regions
(due to the operational cost of the surgery and the surgeon’s
fee, these interventions cost at least V32e100 per surgery,
totaling V37,376e116,800 for 1168 patients.22)
The price of imprint cytology of a lymph node in the
United States in 2010 was (the dollar equivalent of)
V57.23 Based on this data, in our case, the total cost
would be V119,832. If we use the latest intraoperative
histological diagnostic method, nucleic acid amplifica-
tion, it costs V172.50 to examine a lymph node, based
on data from a French survey.24 The cost for the total pa-
tient population was V362,664. Intraoperative histologi-
cal examinations are less effective4,6 and significantly
increase treatment costs for patients operated on for early
breast cancer.
Our study shows that axillary block dissection is only
necessary in the treatment of the axillary region in an
increasingly smaller group of patients (9%), and this per-
centage will further decrease with more extensive use of
alternative axillary radiotherapy.
Based on our results, imprint cytology of the sentinel
lymph node(s) in patients operated on for malignant breast
cancer has no confirmed benefits based on the current
guidelines, and its routine use is not indicated. According
to the latest international guidelines, intraoperative exami-
nation of the sentinel lymph node(s) may be indicated in
the case of mastectomy (when postoperative radiotherapy
is not planned) and after neoadjuvant therapy, as ABD is
still indicated in these cases.Conflict of interest statement
The authors have no conflict of interest or financial
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